Tests for glioma based on the determining concentrations of HIF-1α, ANG-2, and IL-1β will indicate the presence of the disease at higher concentrations of these proteins, because the diagnostic value of each variable increases with concentration. This evidence concerns the gene HIF1A and central nervous system cancer.